# Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation

> **NCT02383355** · PHASE4 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 40 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** Raltegravir
- **DRUG:** Continuation of own regimen

## Key facts

- **NCT ID:** NCT02383355
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-01
- **Primary completion:** 2016-03-31
- **Final completion:** 2017-07-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2019-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02383355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02383355, "Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02383355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*